Tenax Therapeutics, Inc. (TENX)
TENX moved a median of -0.29% 30 minutes after news, and -0.34% by the close. How TENX actually reacts to news — the realized, point-in-time move the market made, measured across 283 labeled events over the last three years with zero look-ahead.
TENX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 260 |
| 30-min | -0.29% | 39% | 276 |
| 60-min | -0.17% | 46% | 281 |
| to close | -0.34% | 47% | 278 |
| Middle 50% of TENX reactions | -1.40% to +1.04% |
|---|---|
| Median reaction (30-min) | -0.29% |
| Measured reactions | 283 |
Half of all Tenax Therapeutics, Inc. news events land between -1.40% and +1.04% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TENX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 14 | 0.00% | 43% | -3.24% |
| Coverage initiations | 55 | -0.41% | 46% | -0.09% |
| Rating reiterations | 30 | -0.75% | 37% | -0.75% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how TENX ranks against every other measured name →
That’s how TENX usually reacts — get an email when it moves on news →Email me when TENX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TENX's baseline. Nothing else.
Recent TENX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K TENAX THERAPEUTICS, INC. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +0.54% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +2.42% | +2.90% | |
| Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference | Press release | GlobeNewswire | +1.68% | +0.56% | |
| Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 | Press release | GlobeNewswire | -13.46% | -11.54% | |
| TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +4.38% | -3.39% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -9.04% | — | |
| Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF | Press release | GlobeNewswire | — | — | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.45% | -5.94% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | -8.91% | |
| Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.15% | -8.91% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | -3.24% | +5.46% | |
| Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.29% | +5.11% | |
| Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 | Press release | GlobeNewswire | -3.24% | +5.46% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +2.36% | -7.71% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +1.44% | +4.90% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | -3.07% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.73% | -2.14% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -1.47% | -0.81% | |
| Form S-8 TENAX THERAPEUTICS, INC. | SEC filing · Form S-8 | SEC EDGAR | -1.73% | -2.14% | |
| Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.47% | -0.81% | |
| Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.09% | +2.14% | |
| Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer | Press release | GlobeNewswire | +0.85% | +3.42% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | +1.61% | |
| Form ARS TENAX THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.45% | +1.61% | |
| Form DEF 14A TENAX THERAPEUTICS, INC. For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | +1.45% | +1.61% | |
| Form DEFA14A TENAX THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +1.45% | +1.61% | |
| Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer | Press release | GlobeNewswire | +1.45% | +1.61% | |
| Form EFFECT TENAX THERAPEUTICS, INC. | SEC filing · Form EFFECT | SEC EDGAR | -1.53% | -4.24% | |
| Form S-3 TENAX THERAPEUTICS, INC. | SEC filing · Form S-3 | SEC EDGAR | -2.37% | -4.96% | |
| Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +12.38% | +20.92% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +12.38% | +20.92% | |
| Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +12.38% | +20.92% | |
| Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference | Press release | GlobeNewswire | -0.34% | -1.97% | |
| Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 | Press release | GlobeNewswire | -1.31% | +1.39% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +1.30% | +9.54% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +3.50% | +6.74% | |
| Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment | Press release | GlobeNewswire | -1.55% | +4.34% | |
| Tenax Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.28% | +3.41% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | — | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | — | |
| Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF | Press release | GlobeNewswire | +2.10% | -3.35% | |
| Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference | Press release | GlobeNewswire | +0.00% | -3.76% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | +2.77% | |
| Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF | Press release | GlobeNewswire | +0.82% | +2.77% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | -1.80% | |
| Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025 | Press release | GlobeNewswire | — | +0.00% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.23% | |
| Form 8-K TENAX THERAPEUTICS, INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.23% | |
| Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +2.23% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TENX section they belong to.
Where else TENX is measured.
TENX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Xencor, Inc. (XNCR) | 285 | +0.09% | 52% |
| NOVELION THERAPEUTICS INC COMMON SHARES (NVLN) | 283 | 0.00% | 42% |
| GEMPHIRE THERAPEUTICS INC COMMON (GEMP) | 282 | -1.00% | 30% |
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Tenax Therapeutics, Inc.'s median reaction calculated?
Every labeled TENX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 283 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of TENX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TENX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.